Literature DB >> 31611184

Bariatric surgery in the elderly: outcomes analysis of patients over 70 using the ACS-NSQIP database.

David M Pechman1, Fernando Muñoz Flores2, Corin M Kinkhabwala3, Ruben Salas2, Robin H Berk3, David Weithorn2, Diego R Camacho2.   

Abstract

BACKGROUND: Bariatric surgery offers patients with morbid obesity and related diseases short- and long-term benefits to their health and quality of life. Evidence-based medicine is integral in the evaluation of risk versus benefit; however, data are lacking for several high-risk patient populations, including the elderly.
OBJECTIVES: This study assessed morbidity and mortality data for patients age ≥70 undergoing laparoscopic sleeve gastrectomy (SG) or laparoscopic Roux-en-Y gastric bypass (RYGB).
SETTING: University Hospital, Bronx, New York, United States using national database.
METHODS: We used the American College of Surgeons-National Surgical Quality Improvement Project database for years 2005-2016 and identified patients who underwent primary SG or RYGB. Patients age ≥70 were assigned to the over age 70 (AGE70+) cohort and younger patients were assigned to the under age 70 (U70) cohort. Postoperative length of stay and 30-day morbidity and mortality were assessed.
RESULTS: A total of 1498 patients age ≥70 underwent nonrevisional bariatric surgery, including 751 (50.1%) SG and 747 (49.9%) RYGB. AGE70+ was associated with increased mortality and increased rates of cardiac, pulmonary, renal, and cerebrovascular morbidity. AGE70+ patients had longer mean length of stay, and were more likely to require transfusion and return to operative room. When stratified by procedure, rates of organ-space surgical site infection, acute renal failure, urinary tract infection, myocardial infarction, deep vein thrombosis/thrombophlebitis, and septic shock were significantly increased in AGE70+ patients undergoing RYGB but not SG. Impaired functional status was associated with increased rates of morbidity and mortality for AGE70+ patients and for U70 patients, although the small number of patients within each category limited statistical analysis.
CONCLUSIONS: Evaluation of risk versus benefit is performed on a case-by-case basis, but evidence-based medicine is critical in empowering surgeons and patients to make informed decisions. The overall rate of morbidity and mortality for AGE70+ patients undergoing bariatric surgery was increased relative to U70 patients. Rates of several adverse events, including acute renal failure and myocardial infarction, were increased in AGE70+ patients undergoing RYGB but not SG, suggesting that SG may be the preferred procedure for elderly patients with organ-specific risk factors. The increased rates of morbidity and mortality observed for patients with impaired functional status supports consideration of functional status when evaluating preoperative risk.
Copyright © 2019 American Society for Bariatric Surgery. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Bariatric surgery; Diabetes; Elderly; Frailty; Functional status; Gastric bypass; Geriatric; Laparoscopic; Roux-en-Y gastric bypass; Sleeve gastrectomy; Weight loss surgery

Year:  2019        PMID: 31611184     DOI: 10.1016/j.soard.2019.08.011

Source DB:  PubMed          Journal:  Surg Obes Relat Dis        ISSN: 1550-7289            Impact factor:   4.734


  2 in total

1.  Comparative Safety and Effectiveness of Roux-en-Y Gastric Bypass and Sleeve Gastrectomy in Obese Elder Patients: a Systematic Review and Meta-analysis.

Authors:  Chenxin Xu; Tong Yan; Hongtao Liu; Rui Mao; Yurui Peng; Yanjun Liu
Journal:  Obes Surg       Date:  2020-09       Impact factor: 4.129

2.  Development of the "OS-SEV90 Score" to Predict Severe Postoperative Complications at 90 Days Following Bariatric Surgery.

Authors:  Hugo Meunier; Benjamin Menahem; Yannick Le Roux; Adrien Lee Bion; Yoann Marion; Antoine Vallois; Nicolas Contival; Thomas Gautier; Jean Lubrano; Anaïs Briant; Jean-Jacques Parienti; Arnaud Alves
Journal:  Obes Surg       Date:  2021-04-28       Impact factor: 4.129

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.